Author: admin

In 2006 Rutger completed his studies in Business Administration at the Radboud University in Nijmegen, and graduated with majors in Strategic Human Resource Management. In 2006 he started working at PwC accountants as financial auditor mainly for SME’s and in Healthcare. At the same time he started his study in Auditing at the Vrije University in Amsterdam.  In 2009 he started working for the Radboud University Medical Center as Senior Projectcontroller and Teamleader for the department of Finance. He helped Principal Investigators and researchers at various departments managing their projects.  In this role he started in 2012 supporting the PanACEA I project. He helped with budgeting, financial reporting and auditing the financial reports from partners. In March 2017 he started working as project manager on PanACEA-II, focusing on consortium coordination, legal en financial.

In 2012 Lindsey completed her studies in Biomedical sciences at the Radboud University in Nijmegen, and graduated with majors in Occupational and Environmental Health and in Toxicology. In august 2012 she started her PhD at the Radboud university medical center, in which she studied the molecular mechanisms underlying (un)wanted transporter mediated drug-drug interactions and assessed the pharmacokinetics and drug-related adverse events of TB drugs as part of multiple drug therapy in TB patients. For the pharmacokinetic studies she spent considerable time at Universitas Padjadjaran and Hasan Sadikin hospital in Bandung, Indonesia, an important partner in tuberculosis research for the Radboudumc. During her PhD Lindsey also completed the training required for the register of professional toxicologists by the Netherlands Society of Toxicology (NVT). After finishing her PhD, in January 2017, Lindsey is continuing her work as a postdoctoral researcher, studying potential new and safe drug regimens against tuberculous meningitis. Furthermore starting from March 2017, she is working as project manager on PanACEA-II, focusing on HIGHRIF1, trial and consortium coordination, drug management, pharmacology, and providing scientific support.

Derek Sloan is a Senior Clinical Lecturer and Consultant Physician in Infectious Diseases at the University of St Andrews. He studied Immunology and Medicine at the University of Glasgow and worked as a junior doctor in Scotland prior to departing for Chogoria Hospital, Kenya and Hlabisa Hospital, KwaZulu Natal, South Africa in 2004-6, where he worked as a clinician with a specialist interest in HIV and tuberculosis. He returned to the UK to complete specialist training in Infectious Diseases at the Liverpool School of Tropical Medicine. From 2008-12 he completed a Wellcome Trust PhD fellowship on the Clinical Pharmacology of TB treatment in Blantyre, Malawi where he also served as a Consultant Physician in the College of Medicine. He currently serves on the British Thoracic Society MDR-TB Advisory Panel and is engaged in several clinical TB research projects in Europe, Africa and Asia.

Dr Marriott Nliwasa is a final year PhD student with the London School of Hygiene and Tropical Medicine. His PhD covers strategies to reduce risk of early death among adults with symptoms suggestive of tuberculosis (TB): i.e. increasing access to HIV testing, TB screening in communities and health facilities, evaluation of new TB diagnostic tests (Xpert MTB/RIF and TB-LAMP) and their impact on patient outcomes. Marriott’s immediate future research focuses on trials of other new TB tests including Xpert MTB/RIF Ultra, digital chest radiography, IRISA-TB (for TB meningitis). Marriott is also involved in trials of new TB drugs and new TB drug regimens under the EU-Africa PanACEA consortium.

Sébastien Gagneux is Associate Professor of Infection Biology and Head of Department at the Swiss Tropical and Public Health Institute (Swiss TPH)/University of Basel. After receiving his PhD from the University of Basel, he worked as a postdoctoral fellow at Stanford University and at the Institute for Systems Biology in Seattle, USA. He then spent three years as a Program Leader at the MRC National Institute for Medical Research in London, UK before joining Swiss TPH. His research focuses on the ecology and evolution of Mycobacterium tuberculosis, and combines population genomics, molecular epidemiology and experimental approaches to study the effect of bacterial variation on host-pathogen interaction and drug resistance.

Blandina Theophil Mmbaga is a Director of Kilimanjaro Clinical Research Institute at Kilimanjaro Christian Medical Centre in Moshi, Tanzania since 2015 and a Director of the KCMC-Duke University Collaboration Clinical Research site in Moshi since 2013. She also works as a pediatrician at KCMC, Senior Lecturer Kilimanjaro Christian Medical University College (KCMUCo) and Adjunct Ass. Professor of Duke Global Health Institute. Blandina had her undergraduate done at the Nizhny Novgorod State Medical Academy in Russia and Pediatric residence at KCMUCo, Tumaini University. She had her doctorate in public health and epidemiology at the University of Bergen in Norway. She is leading several research activities at KCMC and KCRI mainly in infectious diseases (Tuberculosis, HIV/AIDS, Antimicrobial resistant and zoonoses diseases) as well as maternal and child health.

Blandina has a good experience in leading clinical trials in HIV/AIDS and Tuberculosis under her leadership as IMPAACT scientific and immunology committee member 2006-2012 and IMPAACT site PI since 2013 to date. She has a good experience in students supervision and mentorship both masters and PhD levels within KCMUCo and outside Tanzania (UCT, Glasgow, Bergen University, London School and Duke University) as part co supervision within collaborative research capacity building.